A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months. Sponsor Protocol No. mRNA-1273-P206 (BabyCOVE)

Primary Objective

Please see Original Protocol 17Jun2022, Section 3, pages 42-45 for study objectives and endpoints.

Is this Study for You?

Let's Get Started!


The BabyCOVE Study is evaluating an investigational bivalent vaccine. The investigational vaccine cannot make someone sick with COVID-19 and is not a gene therapy, which means it does not cross the nucleus of a cell to integrate with the host genome. The total duration of participation is approximately 15 months and, depending on a participant’s enrollment assignment, 3 brief phone calls, 2 telemedicine visits, and up to 8 clinic visits. All participants will receive 2 injections 8 weeks apart. Those enrolled in Part 1 of the study will receive the investigational pediatric vaccine, and those enrolled in Part 2 of the study will receive either the investigational pediatric vaccine or a placebo. Participants will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation.




In order to enroll in the BabyCOVE Study, an individual must: -Be between 12 weeks and less than 6 months of age and in good health (some health issues are allowed if they are well controlled with treatment and have not changed much recently) -Not have a positive COVID-19 test within 2 weeks prior to receiving the first injection -Be free from exposure to someone with SARS-CoV-2 infection or COVID-19 within 2 weeks prior to receiving the first injection -Not have received an investigational pediatric vaccine or treatment for COVID-19 -Have parent(s)/caregiver(s) who understand and are willing and physically able to comply with protocol-mandated follow-up

Type of Study



Childrens Hospital Colorado

Principal Investigator
Photograph of Elizabeth Mcfarland,  MD

Elizabeth Mcfarland, MD

Study ID

Protocol Number: 22-1736

More information available at ClinicalTrials.gov: NCT05584202

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers